The effect of erythropoietin on normal and neoplastic cells

Steve Elliott, Angus M SinclairOncology Research, Amgen, Thousand Oaks, CA, USAAbstract: Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor (EpoR) resident on the surface of erythroid progenitor cells, thereby promoting erythropoiesis. Recombinant human erythropoi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elliott S, Sinclair AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/909328e983024990acb9ca013b3150e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:909328e983024990acb9ca013b3150e3
record_format	dspace
spelling	oai:doaj.org-article:909328e983024990acb9ca013b3150e32021-12-02T02:55:31ZThe effect of erythropoietin on normal and neoplastic cells1177-54751177-5491https://doaj.org/article/909328e983024990acb9ca013b3150e32012-06-01T00:00:00Zhttp://www.dovepress.com/the-effect-of-erythropoietin-on-normal-and-neoplastic-cells-a10244https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Steve Elliott, Angus M SinclairOncology Research, Amgen, Thousand Oaks, CA, USAAbstract: Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor (EpoR) resident on the surface of erythroid progenitor cells, thereby promoting erythropoiesis. Recombinant human erythropoietin has been used successfully for over 20 years to treat anemia in millions of patients. In addition to erythropoiesis, Epo has also been reported to have other effects, such as tissue protection and promotion of tumor cell growth or survival. This became of significant concern in 2003, when some clinical trials in cancer patients reported increased tumor progression and worse survival outcomes in patients treated with erythropoiesis-stimulating agents (ESAs). One of the potential mechanisms proffered to explain the observed safety issues was that functional EpoR was expressed in tumors and/or endothelial cells, and that ESAs directly stimulated tumor growth and/or antagonized tumor ablative therapies. Since then, numerous groups have performed further research evaluating this potential mechanism with conflicting data and conclusions. Here, we review the biology of endogenous Epo and EpoR expression and function in erythropoiesis, and evaluate the evidence pertaining to the expression of EpoR on normal nonhematopoietic and tumor cells.Keywords: erythropoietin, erythropoietin receptor, tumor, anemia, angiogenesisElliott SSinclair AMDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 163-189 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Elliott S Sinclair AM The effect of erythropoietin on normal and neoplastic cells
description	Steve Elliott, Angus M SinclairOncology Research, Amgen, Thousand Oaks, CA, USAAbstract: Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor (EpoR) resident on the surface of erythroid progenitor cells, thereby promoting erythropoiesis. Recombinant human erythropoietin has been used successfully for over 20 years to treat anemia in millions of patients. In addition to erythropoiesis, Epo has also been reported to have other effects, such as tissue protection and promotion of tumor cell growth or survival. This became of significant concern in 2003, when some clinical trials in cancer patients reported increased tumor progression and worse survival outcomes in patients treated with erythropoiesis-stimulating agents (ESAs). One of the potential mechanisms proffered to explain the observed safety issues was that functional EpoR was expressed in tumors and/or endothelial cells, and that ESAs directly stimulated tumor growth and/or antagonized tumor ablative therapies. Since then, numerous groups have performed further research evaluating this potential mechanism with conflicting data and conclusions. Here, we review the biology of endogenous Epo and EpoR expression and function in erythropoiesis, and evaluate the evidence pertaining to the expression of EpoR on normal nonhematopoietic and tumor cells.Keywords: erythropoietin, erythropoietin receptor, tumor, anemia, angiogenesis
format	article
author	Elliott S Sinclair AM
author_facet	Elliott S Sinclair AM
author_sort	Elliott S
title	The effect of erythropoietin on normal and neoplastic cells
title_short	The effect of erythropoietin on normal and neoplastic cells
title_full	The effect of erythropoietin on normal and neoplastic cells
title_fullStr	The effect of erythropoietin on normal and neoplastic cells
title_full_unstemmed	The effect of erythropoietin on normal and neoplastic cells
title_sort	effect of erythropoietin on normal and neoplastic cells
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/909328e983024990acb9ca013b3150e3
work_keys_str_mv	AT elliotts theeffectoferythropoietinonnormalandneoplasticcells AT sinclairam theeffectoferythropoietinonnormalandneoplasticcells AT elliotts effectoferythropoietinonnormalandneoplasticcells AT sinclairam effectoferythropoietinonnormalandneoplasticcells
_version_	1718402056069316608

The effect of erythropoietin on normal and neoplastic cells

Ejemplares similares